Podcast: Lung Inflammation Caused by CDK4/6 Inhibitors

Moderators

What My Patients Are Asking: What Is the Lung Inflammation Side Effect Caused by CDK4/6 Inhibitors?

December 20, 2019

Brian Wojciechowski, M.D., practices medical oncology in Delaware County, Pennsylvania at Riddle, Taylor, and Crozer hospitals and also serves as Breastcancer.org's medical adviser. A native of South Philadelphia, he trained at Temple University School of Medicine and Lankenau Medical Center. Dr. Wojciechowski is a sought-after speaker on the topics of medical ethics and the biology of cancer.

In September 2019, the U.S. Food and Drug Administration released a statement warning that the CDK4/6 inhibitors used to treat breast cancer:

• Ibrance (chemical name: palbociclib)
• Kisqali (chemical name: ribociclib)
• Verzenio (chemical name: abemaciclib)

may cause rare but serious inflammation in the lungs.

Listen to the podcast to hear Dr. Wojciechowski talk about:

• how CDK4/6 inhibitors are used to treat breast cancer
• why we're just hearing about this side effect now
• he recommendations for anyone being treated with a CDK4/6 inhibitor

Running time: 7:11

Listen now or read the transcript.